ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Midodrine Associated with Increased Mortality on Liver Transplant Waitlist

J. Kalil, M. Hertl, E. Schadde, J. Poirier, N. Alvey, E. Chan.

General Surgery - Transplant, Rush University Medical Center, Chicago, IL.

Meeting: 2018 American Transplant Congress

Abstract number: D212

Keywords: Liver transplantation, Mortality, Waiting lists

Session Information

Session Name: Poster Session D: Liver - Kidney Issues in Liver Transplantation

Session Type: Poster Session

Date: Tuesday, June 5, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Background:

Midodrine is an alpha-1 agonist which induces arterial and venous vasoconstriction. It prevents symptomatic hypotension and is used for treatment of refractory ascites and hepatorenal syndrome (HRS) in cirrhosis. A recent study showed that pre-kidney transplant Midodrine use resulted in increased post-transplant graft failure and death. The current study examines if Midodrine prior to liver transplantation is associated with increased pre- and post-transplant renal failure and pre-transplant mortality.

Methods:

A single center retrospective study was conducted by analyzing the hospital charts of 369 patients on the liver transplant waitlist between 2010-2016. A multivariate analysis was performed with the primary endpoint of pre-transplant renal failure (defined by the requirement of renal replacement therapy, RRT) and secondary endpoints of post-transplant renal failure and waitlist mortality. Confounders were well known risk factors for waitlist mortality such as: diagnosis of chronic kidney disease (CKD), diabetes, HRS, and MELD score (at time of listing and at time of transplant/current).

Results:

Thirty-eight percent of all patients received pre-transplant Midodrine (n=141). The mean age was 54 (range 18-76) which was not significant between the exposed and unexposed groups (p=0.34). Patients with HRS were more likely to receive Midodrine (p<0.001), while there was no association with CKD or diabetes (p=0.86 and p=0.64, respectively). There was no significant association between pre- or post-transplant renal failure and patients who received Midodrine (p=0.9 and p=0.82, respectively). The median MELD at time of listing was 20.5 and at time of transplant/current was 33.5 in the Midodrine group which were both significantly higher than the no Midodrine group (p<0.001). Patients receiving Midodrine had a significantly increased risk of mortality on the waitlist (OR 2.37, 95% CI: 1.18 – 4.8, p=0.02), independent of MELD at listing, MELD at transplant/current, and HRS.

Conclusion:

Patients who take Midodrine while on the liver transplant waitlist do not have increased pre- or post-transplant renal failure. Midodrine use is associated with increased mortality on the waitlist, independent of well-established risk factors for waitlist mortality. The use of this drug in waitlisted patients should be further explored.

CITATION INFORMATION: Kalil J., Hertl M., Schadde E., Poirier J., Alvey N., Chan E. Midodrine Associated with Increased Mortality on Liver Transplant Waitlist Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Kalil J, Hertl M, Schadde E, Poirier J, Alvey N, Chan E. Midodrine Associated with Increased Mortality on Liver Transplant Waitlist [abstract]. https://atcmeetingabstracts.com/abstract/midodrine-associated-with-increased-mortality-on-liver-transplant-waitlist/. Accessed June 2, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences